The Food and Drug Administration has approved Pixclara, a glioma PET imaging drug from Telix Pharmaceuticals. Telix announced the decision in its approval announcement on 14 September 2026. The active ingredient is floretyrosine F 18, also written as 18F-FET. Telix describes the product as the first FDA-approved FET-PET imaging drug for glioma.
The approved wording is narrow and conditional. The approved use comes in three parts. Pixclara is indicated for use with PET “to differentiate recurrent or progressive glioma from treatment-related change”. The label adds that this is “in conjunction with other diagnostic evaluations”. It covers “adults and pediatric patients 1 month of age and older”.
The Prescription Drug User Fee Act target action date was 11 September 2026. Telix issued its release three days later. LSDN found no separate FDA press announcement for the approval as at 15 September 2026. LSDN’s tracker of FDA drug approval decisions had carried the 11 September target date since July.
The decision matters beyond one company. It could close a long-running gap between international neuro-oncology guidance and what American clinicians can buy. Telix has not yet said when the product will be available. The approval also leaves the UK question entirely open.
What the FDA approved
Pixclara targets the L-type amino acid transporters LAT1 and LAT2, which are regularly overexpressed in gliomas. Radiologists use the resulting signal to separate live tumour from radiation necrosis and other treatment effects. That distinction is the central problem in follow-up imaging after chemoradiotherapy. Telix operates in radiopharmaceuticals, a field reshaping cancer treatment. Its approved products are diagnostics, while its therapies remain investigational.
Telix reports that safety was evaluated in 382 glioma patients. Of those, 371 were adults and 11 were paediatric patients. The mean age was 57 years, with a range of 5 to 86 years. The most common adverse reaction was headache, at 0.5 per cent. Nausea, injection site reaction, fatigue and malaise each occurred in fewer than 0.5 per cent of patients.
The label reaches down to one month of age. The safety database contains 11 paediatric patients, and the youngest patient studied was five. LSDN notes that gap between the studied and approved populations and draws no conclusion from it. Telix links to full prescribing information on its website, which LSDN could not access directly. The label had not yet appeared on DailyMed as at 15 September 2026.
Kevin Richardson, Chief Executive Officer of Telix Precision Medicine, framed the decision as an access event. He said approval “will enable broad access in the U.S. to FET-PET imaging”. He added that the technique is “already recognized in international clinical practice guidelines”. The release also quotes Patrick Wen of Mass General Brigham Cancer Institute. Wen holds the E. Antonio Chiocca, MD, PhD, Family Endowed Chair in Neuro-Oncology. Both comments come from the sponsor’s own announcement.
A second pass at the same application
The regulatory history is the longer story. Telix announced Orphan Drug designation on 6 October 2020. It announced Fast Track designation on 16 April 2024. Telix filed the original New Drug Application on 28 August 2024. It announced acceptance with Priority Review on 24 October 2024.
That first glioma PET imaging application failed. Telix disclosed a Complete Response Letter on 28 April 2025. The company said the FDA had ruled that the application “cannot be approved in its current form”. Telix reported that the agency stated “additional confirmatory clinical evidence is required”. The same announcement recorded that the FDA “has not raised any concerns regarding product safety”.
Telix said it would request a hearing to review the basis for the decision. It also said it remained committed to supplying patients through an FDA-approved expanded access programme. In September 2025 the company said it had agreed a resubmission pathway with the FDA. Telix described the route as “an additional confirmatory efficacy study analysis of existing data”.
The company resubmitted in March 2026. Telix announced on 10 April 2026 that the FDA had accepted the resubmission. The agency set a goal date of 11 September 2026.
What the releases state, and what they do not
Telix says the resubmission combined additional data and statistical analysis with the primary data set from the original filing. No new prospective registrational study is named in any of the company’s announcements. LSDN found no published FDA review documents for the application as at 15 September 2026. On that record, LSDN draws no conclusion about what changed the outcome.
Guidelines already recommend amino acid PET
International glioma PET imaging guidance predates this approval by years. A Journal of Nuclear Medicine review by Norbert Galldiks and colleagues sets out why 18F-FET spread so widely. Carbon-11 methionine has a half-life of roughly 20 minutes and needs an on-site cyclotron. Fluorine-18 has a half-life of about 110 minutes, so doses can be shipped to other centres.
The same review reports that use of 18F-FET “has multiplied”, replacing carbon-11 methionine especially in Europe. The authors also summarise how well the tracers separate relapse from treatment effects in glioblastoma. In studies using 18F-FET or 18F-FDOPA PET, the distinction was made correctly 80 to 90 per cent of the time.
Galldiks and co-authors returned to the question in a 2025 Neuro-Oncology editorial. It accompanied the updated RANO working group and EANO recommendations. The authors note that most amino acid PET studies are retrospective, small and often single-centre. They call for prospective multicentre studies to establish higher-level evidence. They also point to the PET RANO 1.0 response criteria, published in 2024. At the same time, they welcome efforts to make amino acid PET more widely available.
Both papers carry declared links to Telix. Galldiks reports advisory board honoraria from the company in each. The 2025 editorial also lists Telix research funding for co-author Nathalie Albert. Taken together, the glioma PET imaging evidence base is broad and practical, but mostly retrospective. Neither Telix nor the FDA has publicly linked that evidence profile to the terms of the approval.
The safety wording on both sides
Sponsor messaging and label warnings for this glioma PET imaging drug emphasise different things. Richardson said Pixclara would give physicians “more certainty in their diagnoses”. The release also reports a very low adverse reaction rate. Its warnings section is more cautious.
Telix states that image misinterpretation may occur. A negative image does not rule out glioma, and a positive image does not confirm it. Equivocal findings may produce false results. Clinicians are told to correlate findings with histopathology, cross-sectional imaging and clinical history. The document also warns that the agent adds to cumulative radiation exposure, and advises hydration and frequent voiding.
Those two framings sit in tension. The executive message stresses certainty. The approved indication describes an adjunct to other diagnostic evaluations. LSDN reports both and takes no position on how clinicians will weigh them.
Why the UK glioma PET imaging question stays open
No UK marketing authorisation covers this glioma PET imaging drug. An LSDN search of the electronic medicines compendium returned no fluoroethyl-L-tyrosine product as at 15 September 2026.
Europe is further along. Telix submitted a European marketing authorisation application in February 2026, under the proposed brand name Pixlumi. France’s ANSM acts as Reference Member State, coordinating the assessment with concerned member states. Telix announced validation in late April 2026, alongside a 210-day active assessment phase. That period excludes clock stops. National authorisations are expected to follow a positive outcome.
The UK sits outside that procedure. LSDN found no Telix statement on an MHRA filing as at 15 September 2026. A route does exist in principle. The MHRA International Recognition Procedure recognises the FDA as a Reference Regulator. Its Recognition A timetable runs to 60 days with no clock stop. That applies where the reference regulator approved within the preceding two years, among other conditions.
The guidance also lists triggers that push an application onto the slower Recognition B route. That route runs to 110 days, with one clock stop at day 70. First-in-class new active substances appear among the listed triggers. LSDN notes that wording and draws no conclusion about which route this product would take.
English guidance is the other obstacle. NICE guideline NG99 was published on 11 July 2018 and last updated on 29 January 2021. Its glioma follow-up section addresses imaging for suspected recurrence. Recommendation 1.3.4 covers standard structural MRI in regular clinical review. Recommendation 1.3.5 says to consider advanced MRI techniques where standard imaging is unclear. PET is not mentioned in the recommendations at all. That is an LSDN observation about the guideline, not a NICE position on this product.
Capacity before access
Even an approved glioma PET imaging tracer would meet constrained PET-CT capacity in England. A 2026 analysis in BJR Open modelled English PET-CT demand across all indications at 361,900 scans a year. Actual provision in 2021 was 239,367 scans. The authors are Nadia Smith, Rebecca Nutbrown, Alba Eisner and Raj Jena. Jena is Clinical Professor of AI in Radiotherapy at the University of Cambridge. He is also a consultant clinical oncologist at Cambridge University Hospitals.
Supply logistics matter as much as approval. A fluorine-18 tracer must be produced regionally and delivered within hours. Telix’s approval release does not say when Pixclara will reach customers. It does not name the network that will carry it.
What to watch
Several questions about glioma PET imaging access follow directly from this week. The first is availability and price in the United States, neither of which Telix has disclosed. The second is a DailyMed listing, allowing independent review of paediatric dosing and the full warnings.
The European outcome follows the 210-day assessment, which excludes clock stops. It will show whether a second regulator agrees on the breadth of the label. Any MHRA filing, and the route chosen, would set the earliest realistic UK date. Telix says the FDA has cleared an investigational new drug application for a Phase 3 study in brain metastases. That study could widen the indication later. For UK trade readers, the licensing question and the capacity question need answering together.
